A Novel Treatment for Children with Anaplastic Wilms’ Tumor

Already funded by the Lekofsky Family Foundation!

An unmet clinical need exists for children with Wilms’ tumor that present with anaplastic (unfavorable) histology. While traditional chemotherapeutic treatment for histologically favorable Wilms’ tumor has seen great success, many children presenting with anaplastic disease fail to respond to therapies. Anaplastic Wilms’ tumor has relatively little resource development, basic science or translational research compared to other forms of childhood cancer. Our ongoing studies are designed to provide a strong rationale for moving this BRD4 inhibitor – irinotecan therapeutic combination strategy into the clinical setting.